Professor Eyal Gottlieb is the Director of the Cancer Metabolism Research Unit at Cancer Research-UK, Beatson Institute (Glasgow, UK). He received his BSc in Agricultural Sciences at the Hebrew University of Jerusalem in 1990 and MSc (1992) and PhD (1998) degrees in Molecular Cell Biology at the Weizmann Institute of Science (Rehovot, Israel) where he studied the role of the tumour suppressor, p53, in apoptosis. In 1998 Prof Gottlieb moved to the University of Chicago (Chicago, USA) as an EMBO postdoctoral fellow to study metabolic regulation of cell death and in 1999, he moved to the University of Pennsylvania (Philadelphia, USA) to continue his postdoctoral studies., There he became, in 2000, a Leukemia and Lymphoma Society Special Fellow. In 2003, Prof Gottlieb was appointed a Research Group Leader at the Cancer Research-UK, Beatson Institute where he studied cancer metabolism. He became a Professor of Molecular Cell Biology at the University of Glasgow in 2009.
Prof Gottlieb and his team combine analytical chemistry and biochemical approaches to study metabolic transformation of cancer. His group generated and employed mouse models and cell lines to study the metabolic consequences and vulnerabilities due to the loss of the mitochondrial tumour suppressors, FH and SDH and due to changes in tumour microenvironment conditions and intracellular metabolic demands. Their major discoveries were: the identification of onco-metabolic signalling events mediated by TCA cycle metabolites; the discovery of metabolic adaptations and survival mechanisms of FH-deficient cancer cells; and the tight control of glycolysis and serine biosynthesis in cancer.